
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded frozen oral preparation containing tetracaine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing tetracaine are listed in solution and cream forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Tetracaine is an ester-type local anesthetic that compounding pharmacies prepare in topical numbing creams, gels and ointments, often combined with lidocaine or benzocaine.
Tetracaine is an amino-ester local anesthetic. It blocks sodium channels on nerve fibers so that pain signals cannot start or travel, producing numbness where it is applied. It is lipid soluble and relatively potent, with a quick onset and long duration among the ester anesthetics. Manufactured tetracaine hydrochloride products include an ophthalmic solution, FDA-approved for procedures requiring a rapid, short-acting topical eye anesthetic, Kovanaze, a tetracaine and oxymetazoline nasal spray FDA-approved for dental anesthesia of the upper teeth, and Pliaglis, a lidocaine and tetracaine cream FDA-approved for topical analgesia on intact adult skin before superficial dermatologic procedures such as filler injection and laser treatment. Tetracaine injection for spinal anesthesia is marketed as an unapproved drug. Prescribers may order tetracaine compounded in a topical cream, gel or ointment at a strength or in a vehicle not manufactured, often with lidocaine and benzocaine. Compounded tetracaine preparations are not FDA-approved and require a prescription.
Tetracaine labels carry no boxed warning. Tetracaine belongs to the local anesthetic class that carries a methemoglobinemia warning: the Pliaglis label describes cases, with higher risk in infants under 6 months, people with G6PD deficiency and those taking nitrates, dapsone, sulfonamides or other local anesthetics. Absorption rises with larger areas, longer application times and broken skin; keep it away from eyes, mucous membranes, children and pets. Prolonged eye use can permanently damage the cornea. Class I antiarrhythmics add to systemic effects. People allergic to ester anesthetics or PABA should not use it. No data on use in pregnancy are available (Pliaglis label); a drugs.com breastfeeding review considers topical use away from the breast unlikely to affect the infant. For redness or burning at the site, talk to your prescriber or pharmacist; seek care right away for blue or gray skin, shortness of breath or ringing in the ears.
Tetracaine is an amino-ester local anesthetic (pKa about 8.46, high lipid solubility, about 75 percent protein bound) that blocks voltage-gated sodium channels, preferentially in the open state. It is hydrolyzed rapidly by plasma pseudocholinesterase, with a minor red-cell esterase contribution, to para-aminobenzoic acid and diethylaminoethanol; minimal unchanged drug reaches the urine, and no half-life is established. After the labeled Pliaglis application to intact skin, tetracaine plasma levels were below the assay limit. Labeled indications: tetracaine hydrochloride ophthalmic solution for short ocular procedures; Kovanaze (tetracaine and oxymetazoline) nasal spray for regional anesthesia during restorative procedures on the upper teeth; Pliaglis (lidocaine and tetracaine) for topical analgesia on intact adult skin before superficial dermatologic procedures; tetracaine injection (unapproved marketed drug) for spinal anesthesia. Prescribers have ordered compounded topical tetracaine, alone or with lidocaine, before dermatologic and aesthetic procedures; StatPearls lists off-label tetracaine use for corneal abrasion and before pediatric venipuncture. Strength, surface area and application time are per prescriber, with total absorbed anesthetic from all sources considered. Monitoring: signs of local anesthetic systemic toxicity (perioral numbness, tinnitus, seizures, bradycardia) and methemoglobinemia (cyanosis, chocolate-colored blood, low oxygen saturation unresponsive to oxygen); concurrent sulfonamides, whose antibacterial activity PABA can reduce. Not a controlled substance.
Keep the popsicle frozen until it is time for a dose and take it as your label directs. Do not share popsicles. Ask the pharmacist if you are unsure how to use it.
Store in the freezer in the original container and out of reach of children. The pharmacy sets the beyond-use date; it is printed on the label. Discard any left after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Eat one popsicle